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Accepted 29 March 2020Malaria burden has significantly changed or decreased over the last 20 years, however, it re-
mains an important health problem requiring the rigorous application of existing tools and ap-
proaches, as well as the development and use of new interventions. A malaria vaccine has long
been considered a possible new intervention to aid malaria burden reduction. However, after
decades of development, only one vaccine to protect children has completed phase 3 studies.
Before being widely recommended for use, it must further demonstrate safety, impact and fea-
sibility in ongoing pilot implementation studies. Now is an appropriate time to consider the
use-cases and health targets of future malaria vaccines. These must be considered in the con-
text of likely innovations in other malaria tools such as vector control, as well as the significant
knowledge gaps on the appropriate target antigens, and the immunology of vaccine-induced
protection. Here we discuss the history of malaria vaccines and suggest some future use-
cases for future malaria vaccines that will support achieving malaria health goals in different
settings.
© 2020 The Authors. Published by Elsevier Ltd on behalf ofWorld Federation of Parasitologists. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords:
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Innovation1. Malaria control and elimination
In 2015, the global technical strategy (GTS) of WHO called for elimination of malaria in 20 countries by 2025, and 35 by 2035,
and reduction of at least 90% of clinical incidence and mortality in the remainder (Bhatt et al., 2015). These targets were set fol-
lowing dramatic reduction over 15 years of malaria incidence, mainly as a result of integrated large scale-up of insecticide treated
nets, indoor residual spraying, and artemisinin combination therapy (Bhatt et al., 2015). In many areas where previously most
people were infected for most of the time, prevalence has become patchy, and the burden of disease has shifted from the youn-
gest children to older age-groups (Mogeni et al., 2016; Nkumama et al., 2017) .
Recently, however, overall progress in reducing Plasmodium falciparum mortality and clinical incidence has stalled (World
Health Organization, 2017) and the WHO world malaria report estimated that 2016 there was an increase in clinical cases in
many regions. History shows that there are many potential causes of resurgence (Cohen et al., 2012), including resistance, reduc-
tions in intervention coverage reflecting funding gaps, and also the intrinsic dynamics induced by many interventions (such as
delaying acquisition of natural immunity), which have maximal impact soon after scale-up.
Drug resistance is currently a particular worry in the Mekong, with artemisinin resistance and resistance to partner drugs pres-
ent and increasing (Ménard et al., 2016). There is concern about artemisinin resistance spreading to, or emerging in, Africa, as wasny).
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2020; Moyes et al., 2019).
Novel insecticide and/or vector controls, as well as new drugs, may soon enter phase 3 studies, however, the development
pathway for these is potentially long and uncertain, making the timeline to availability, as well as the affordability of these
tools, unsure. Other new tools such as monoclonal antibodies are also in very early development, and their future product devel-
opment pathway or potential protection will become apparent with forthcoming early clinical studies (Kisalu et al., 2018; Tan
et al., 2018).
2. Expectations and realities of malaria vaccines to date
A malaria vaccine has long been seen as a potential game changer in the fight against malaria, although vaccine development
began at a time when the emphasis in international health was shifting from immediate goal of world-wide malaria eradication to
control, with the Alma-Ata agreement focusing on primary health care (World Health Organization, 1978). In the shadow of the
war in Vietnam, the main institutional support for a malaria vaccine in the 1970s came from the US military's Walter Reed Army
Institute of Research, with the hope being that a very short course of vaccination could provide complete protection against in-
fection for the military and short-term visitors to endemic areas. Following on the pioneering work of the Nussenzweigs
(Nussenzweig and Nussenzweig, 1984; Nussenzweig et al., 1967), the early candidate vaccines were based on sporozoite antigens,
however it became evident that it was not straightforward completely blocking infection with such a vaccine (Ballou et al., 1987;
Hoffman et al., 1987). It was not until 1997 that partial efficacy of the main candidate, RTS,S (based on the P. falciparum
circumsporozoite surface protein, and known as a pre-erythrocytic or anti-infective vaccine), could be established in humans
(Stoute et al., 1997).
There was a perception that vaccines targeting other antigens, especially those of the blood stages of the parasite, might be
more successful (Saul et al., 1999; Genton and Reed, 2007). These were perceived as protecting the most vulnerable from disease,
children under 5 years of age in endemic areas, who suffered the bulk of severe malaria and mortality. A leaky vaccine appeared
an option, especially if responses to blood stage antigens could be used to reduce the incidence of severe disease, even if trans-
mission was barely affected. But during the 1990s, few vaccine candidates reached the field; mainly phases 1 and 2a, b and only
one, SPf66, undertook a phase 3 trial in infants (Genton and Reed, 2007; Acosta et al., 1999a). The latter trial of SPf66 supported
learnings and thus guidance on how to carry out GCP and DSMB clinical studies on infant vaccines in a rolling design from phase
1 to 3 including investigating safety and immunogenicity with EPI vaccine interactions (Acosta et al., 1999b). Those vaccine can-
didates based on synthetic peptides (Alonso et al., 1994; Nosten et al., 1996) or recombinant proteins that combined sporozoite
antigens with blood stages (Saul et al., 1999; Stuerchler et al., 1995; Genton et al., 2002), had mixed results. The availability of the
malaria genome opened up the prospect of DNA vaccines (Doolan et al., 1997) encoding a wide range of malaria antigens, but
initial clinical studies of these were no more encouraging (Epstein et al., 2002; Long and Hoffman, 2002) and prime-boost strat-
egies with adenoviral vectors and modified vaccinia virus (Dunachie and Hill, 2003; Bejon et al., 2005) were also disappointing.
When substantial funding again became available for malaria vaccine development at the start of this century, RTS,S remained
the most advanced candidate. With the realisation that preventing initial infection of the human could be an effective approach in
reducing disease burden it was reconceptualised as a morbidity control tool for young children, and enrolled in a clinical devel-
opment pathway aiming at licensure as a paediatric vaccine. Delivery of RTS,S to infants or children via the expanded program of
immunization (EPI) also offered a novel strategy for delivering malaria interventions, and is a proven mechanism for reaching
children with high coverage of DTP3 vaccines in many countries that are also endemic with malaria. RTS,S consistently demon-
strated partial protection in a series of randomized controlled trials (Bojang et al., 2001; Alonso et al., 2004; Bojang et al.,
2009; Agnandji et al., 2011; Agnandji et al., 2012; RTSS Clinical Trials Partnership, 2015; Abdulla et al., 2008), remaining ahead
of a growing field of other potential vaccines. Now administered with the AS01 adjuvant, RTS,S completed phase 3 clinical studies
in 2015, culminating in the largest clinical studies in children ever conducted in Africa (RTSS Clinical Trials Partnership, 2015).
The long delays inherent in vaccine development have always meant that we are testing vaccines that are aligned with prior-
ities set at least a decade previously. When the goal of eradication returned to the fore in the last decade (Roberts and Enserink,
2007), achieving sterile protection again became a focus of vaccine developers (Hoffman et al., 2015). However the phase 3 study
of RTS,S/AS01 in over 16,000 children in seven African countries demonstrated only moderate clinical efficacy over the 32 months
of follow-up with a higher efficacy in a 5–17 month-old cohort compared to a 6–12 week cohort (RTSS Clinical Trials Partnership,
2015). Extensive modelling results indicated that routine immunization of children with RTS,S/AS01, is potentially cost effective in
areas of moderate to high prevalence (Penny et al., 2016) depending on other interventions in place, and RTS,S/AS01 received a
positive scientific opinion from the European Medicines Agency in 2015. However the protection profile of RTS,S/AS01 is not sat-
isfactory, with rapid waning of antibody levels and efficacy declining over time (RTSS Clinical Trials Partnership, 2015; Penny
et al., 2015; White et al., 2015). The World Health Organization recommended further pilot studies to evaluate safety, impact,
and feasibility in implementation (World Health Organization, 2016), and these began in Ghana, Kenya, and Mali at in the first
half of 2018, aiming to vaccinate roughly 360,000 children per year via routine systems (World Health Organization, n.d.;
https://www.who.int/malaria/media/malaria-vaccine-implementation-qa/en/, n.d.). These pilot studies will estimate impact on se-
vere disease and potentially mortality in real implementation outside highly controlled clinical studies and provide insights into
implementation of a malaria vaccine at large. This means we will gain estimates of vaccine effectiveness, not just clinical efficacy
as observed in the Phase 3 studies. The policy recommendation and the future position and role of RTS,S/AS01 for childhood vac-
cination will depend on these pilot studies.
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Panel on Tools for Malaria Elimination, 2017; The malERA Consultative Group on Vaccines, 2011) and in the context of the GTS
elimination targets, morbidity control in the youngest children may no longer be the most promising use case for a partially pro-
tective pre-erythrocytic vaccine like RTS,S.
3. Innovation and the future
The vaccine candidates currently in development (Draper et al., 2018) include anti-infective vaccines other than RTS,S, such as
attenuated or irradiated whole sporozoite vaccines (PfSPZ), or RTS,S like vaccines such as R21 (Collins et al., 2017). Potentially
potent monoclonal antibodies identified are generally also anti-infective antibodies as they come out of decades of anti-
infective vaccine development.
There remains a need for the identification of new targets and chemistries for malaria vaccines, but until now the health
returns on investments in vaccine development and clinical studies have been less than satisfying. Nevertheless, they have deliv-
ered enormous knowledge gains and impressive technical advances, in the fields of both cellular and humoral immunology
(Draper et al., 2018; Beeson et al., 2019), and recently it is has been recognized there is pertinent need to focus on obtaining
more understandings of malaria immunity, protection and relationship with pre-exposure (Beeson et al., 2019). Controlled
human malaria infection studies have driven advances in both systems biology and immunology that are valuable not just for ma-
laria vaccine and anti-malaria drugs, but also for other diseases.
Many bio-medical research questions remain to be answered. The search continues for bio-markers or immune correlates of
protection that can be easily measured substantially reducing the costs of clinical development. The challenge that this represents
is highlighted by recent studies on the variation in immune responses between populations (Kurtovic et al., 2019) and findings
that the clinical outcomes of vaccination may be largely driven by individual-level variation in immune responses. Innate host im-
mune fitness may be of critical importance, both in determining the response to vaccination, and vulnerability to disease.
Rather than focusing on only identifying and developing new antigens, efforts should also center on understanding the limi-
tations and successes of vaccines been done by re-analyzing immunological samples from past studies to understand the roles
of individual and population genetics or immune fitness. For example, a recent study undertook a comprehensive reanalysis of
blood samples from Tanzanian and Mozambican children in the RTS,S malaria vaccine phase 3 trial. Immune profiling and
transcriptomic analysis identified factors, including age, location and anemia, that shape immune development, and further com-
pared results to Dutch children (Hill et al., 2020). Such important studies require public sharing of samples and data, analogously
to renewed analysis of old drugs in the area of chemotherapy.
Prioritisation of new products should be driven by rational criteria, and vaccines with short durations of effect, requiring a high
number of doses, are less likely to meet criteria of cost-effectiveness or budget impact analyses. The economics of manufacturing,
including both production costs and economies of scale should not be ignored. But innovation is not only taking place in basic
science and product development, but also in its translation to endemic countries. Clinical studies in Africa have led to huge ad-
vances in the technical capacity of local laboratories. Even the Good laboratory practices mosquitoes required to produce PfSPZ
irradiated sporozoites are being produced in endemic countries. Innovations are making novel delivery mechanisms practicable,
such as skin patches, which could reduce the numbers of contacts required with health staff during the vaccination schedule.
For this reason, a novel product that currently appears to be operationally infeasible should not be a priori precluded from testing
and development. Innovation in the use of mathematical modelling will also support exploring multiple use cases and to itera-
tively support assessing candidates, this includes going beyond traditional scenario analysis and using modelling early in develop-
ment rather than when vaccines are already in clinical studies.
All this requires innovation in firstly identifying priority public health needs and secondly defining the use-cases for vaccines
or monoclonal antibodies to achieve these health goals, thus identifying the settings, target ages-groups or populations, and the
system of delivery to the population. These use-cases require consideration of health outcomes and needs other than incidence
of clinical malaria in children and lives-saved or mortality (Moorthy et al., 2013), for instance the objectives might be to reduce
the time to elimination, or delay resurgence (Box 1, Figs. 1–2). In turn, this means that people of all ages might need to be vac-
cinated. The next sections of this paper outline the state of knowledge for some of these alternative future use cases.
4. Alternative use cases
4.1. All-age vaccination to support local elimination programs
The immediate future of malaria vaccines will be to move beyond the childhood age group on which clinical development has
so far focused. Mathematical models of generic anti-infective vaccines have indicated that these have the potential to dramatically
reduce transmission when used in as a mass intervention in low prevalence settings (Penny et al., 2008). If the initial prevalence
is very low, vaccination might interrupt transmission in isolated communities (Penny et al., 2008). In this vein, a trial of mass vac-
cination with PfSPZ has been planned in Bioko Island (Olotu et al., 2018), Equatorial Guinea aiming to test its role in an interven-
tion package for elimination. Now that we know the profile of the effect of RTS,S, it is possible to estimate likely impacts in
specific places to reduce burden, and where inclusion of mass vaccination in surveillance response packages may effectively
drive elimination.
Box 1
Estimated impact of mass vaccination with and without mass drug administration.
Using a modified Ross-Macdonald model of malaria (Dietz, 1988; Allen, 1994) the effects of mass vaccination alone were com-
pared to mass drug administration alone, or to the combination of both interventions.. The model is represented by a set of dif-
ference equations describing susceptible-infected-susceptible malaria dynamics with the number of infectious individual, It, at
time t, in the absence of an intervention represented by
Itþ1 ¼
β
N
It N−Itð Þ þ γIt
Here β (β N 0) is the transmission parameter representing the number of new infections per infected individual at the next time
step, γ(0 b γ b 1) is the proportion of population that remains infectious at the next time, and N the total human population.
Case-management is incorporated by decreasing γ and thus accounting for removal of infections through standard case man-
agement. We assume the length of infection and thus infectious period of 200 days. The susceptible population is given by S-
t = N− It. The basic reproduction number a measure of initial transmission intensity in this model, represents the number of
secondary infections resulting from a single infection, and in this simplified model with no intervention is given by
R0 ¼
β
1−γ
:
Wemodel mass treatment and mass vaccination with a anti-infective vaccine by altering (1) to include terms representing in-
fection prevention and parasite clearance, namely,
Itþ1 ¼ 1−ϵtð Þ
β
N
It N−Itð Þ þ 1−ρtð ÞγIt
where ρt represents probability of clearing infections in the infectious population and is a combination of MDA coverage
and decay of drug efficacy, such that with noMDA ρt=0, and if coverage and efficacy were 100% then ρt=1. The term ϵt
represents the probability of preventing new infections in the susceptible population and is given by vaccination cover-
age and probability of prevention against infection at time twhen the strategy includes vaccination, or is given by drug
coverage and short-lived efficacy of prophylaxis if drugs are delivered without vaccination.
Three yearly applications of one round of each strategy were deployed in the models, with strategies including vaccination as-
suming 3 doses in the first year of vaccination (as is with current childhood vaccination in the Pilot studies or SMC vaccine tri-
als), to reach a high initial efficacy (85–91%) against infection with RTS,S or similar vaccine (Penny et al., 2015; White et al.,
2015), Vaccine efficacy was assumed to decay bi-phasically such that initial decay is quick followed by a slower decay, with a
half-life of approximately 7months (Penny et al., 2015). Drug efficacy of 100%was assumedwith immediate clearance of blood
stage parasites with an additional prophylaxis effect preventing infection that decayed exponentially with a half-life of 10 days.
When drugs were deployed with vaccines, drugs were given either for all three years, or only the first year.
We simulated impact of the interventions on the number of infectious individuals and thus calculated all age prevalence as well
as time till interruption of transmission (if it occurred).We assumed perennial transmission, a population of 10,000 individuals,
and simulate a range of R0 (by altering β) and a range coverages of 3 years of mass intervention strategies. Disease dynamics
were followed for 10 years and interruption of transmission was assumed to occur if prevalence was below 0.1%. Mosquito dy-
namicswere notmodelled explicitly as these vaccines and drug based interventions are assumed to not kill mosquitos and thus
do not alter the force of infection β. Stochasticity can be added to themodel, butwill have little effect on the overall conclusions,
and only adds variation to estimates of extinction time. This simple model account for vaccine effect and decay, but does not
account for natural immunity development and decay, nor the vast range of heterogeneities expected in malaria such as age,
transmission, spatial effects etc. However, the model is sufficient as a cornerstone to begin to explore dynamics of combining
interventions and prompt analysis with more detailed models.
The results suggest that if interruption of transmission is not achieved prevalence resurgences to initial levels (Fig. 1), consistent
with previous modelling results for MDA (Brady et al., 2017). At 70% coverage, a lower level of prevalence is achieved in inter-
ventions including drugs, indicating mass vaccination is less effective than MDA alone in overall reduction of transmission.
Addingmass vaccination toMDA strategieswill potentially 1) result in a lower level of prevalence at the end of 3 years (compare
Fig. 1b and c–d), 2) keep prevalence levels lower for longer (compare Fig. 1a and d), 3) result in being more likely to interrupt
transmission for lower coverages (Fig. 2), and 4) possibly achieve interruption in shorter time periods (Fig. 2). Using drugswith
vaccination in all three rounds is better than for only one round (Fig. 1c–d).We conclude there is added, and possible synergistic
benefit to consider dual rollout of MDA and anti-infective vaccines.
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Fig. 1. Predicted all age prevalence during and following three years of mass interventions for different strategies a) MDA alone for three years (one dose per year),
b) vaccine alone for three years, c) vaccine for three years with drugs only the first year, d) vaccine and drugs every year for three years. Coverage of 70% for each
intervention was assumed over a range of initial R0 values from 1 to 3. Initial R0 is indicated by colour, with the darker the colour the lower the transmission level.
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with impact and cost-effectiveness. Additional hurdles in using any vaccine in mass campaigns are questions about immune re-
sponses, longevity and protection in adults, across populations and settings, and in vulnerable populations such as pregnant
women, malnourished individuals and/or HIV-infected individuals, as well as compliance which may be lower than for drug ad-
ministration campaigns. Therefore, more evidence for the impact and cost effectiveness of these anti-infective vaccines when used
in combination with drugs and reactive interventions in aiding elimination must be collected, but the potential use of a vaccine
under these intervention strategies must be considered seriously in light of the current complex situation for malaria.4.2. Combination with or alternative to seasonal malaria chemoprevention for morbidity and mortality prevention
There has been recognition of the potential impact of adding/integrating anti-infective vaccines like RTS,S to existing interven-
tion strategies (Greenwood et al., 2017). Seasonal malaria chemoprevention (SMC) is used to protect children from 0–5 (and re-
cently 0–10), with the idea being to treat these children in the seasonal treatment of malaria with 1–3 rounds of a drug which
clears and then prevents infection. Despite protection being shorter lived than expected, RTS,S offers longer term prophylaxis
than any existing drugs, and it has been recognized as a possible alternative to or in addition to drugs in seasonal malaria che-
moprevention (SMC) (Greenwood et al., 2017). Different combinations are currently being trialed in Mali and Burkina Faso,
with questions concerning whether a vaccine can replace SMC treatment or increase impact if added in addition. It is not obvious
how the effectiveness of such a strategy compares with SMC drugs alone, whether it is synergistic with the drug treatments,
whether the addition of a vaccine can reduce the number of visits through a child's early years, and whether the cost effectiveness
of these strategies compare. In addition, since strategies like SMC only address seasonal malaria settings, there is a need to
Fig. 2. Visualisation via heat map of the estimated time until transmission is interrupted (prevalence below 0.1%) for a range of coverages and transmission levels
as a result of three years of mass interventions for a) MDA alone for three years or b) mass vaccination with MDA for each year, up to three years. Estimates of
malaria interruption time for a range of yearly intervention coverage and initial R0, with colour indicating time to interruption with the darker the colour
indicating earlier interruption. No interruption occurred after 4 years as interventions ceased by year 3. No interruption of transmission was observed in the
vaccination only strategies.
6 M.A. Penny et al. / Parasite Epidemiology and Control 10 (2020) e00145develop solutions for non-seasonal settings. This will require longer-acting high efficacy vaccines or monoclonal antibodies (with
or without drugs).
4.3. Combination with mass drug administration for elimination and preventing infection
The use of vaccines as mass interventions, in addition to and combined with drug administration but not as a substitute, may
make otherwise unachievable elimination targets reachable, especially when combined with surveillance response packages. Re-
cently this has been considered for aiding elimination in artemisin resistance areas such as the Mekong (Thu et al., 2017), and
vaccination campaigns in addition to MDA might be considered (Gosling and von Seidlein, 2016).
Box 1 below uses a simple model of malaria dynamics to illustrate the likely effects of the use of an anti-infective vaccine in
combination with mass-drug administration (MDA). Figs. 1 and 2 suggest there is potential of synergism between the two inter-
ventions, with the addition of a vaccine increasing public health impact and chances of elimination. The mass drug action com-
ponent clears a large number of infections from a population and vaccine, (even with duration of protection against infection
less than one year) has a substantial impact on delaying resurgence. Further investigations are needed with models accounting
for complex heterogeneities in immunity, malaria transmission, including importation of infections, seasonality and different
health system strengths. But our preliminary results prompt questions to be asked about the combination tool use cases of
anti-infective vaccines.
4.4. Combination of different vaccine effects for several health goals
A polyvalent vaccine directed at several stages of the parasite lifecycle, has long been seen as a potentially transformative in-
tervention (Parker et al., 2001). In principle, anti-infective effects, blocking of merozoites or trophozoites, and/or and effects
against gametocytes within humans, or blocking sporozoite development within the mosquito, might be combined in the same
product. But this remains a distant goal that should be pursued only with the awareness that the limits to vaccine impact imposed
by focusing on a single stage may be less important than the duration of effect and the costs and feasibility of deployment.
Over the last 5–10 years there has been an increase in pre-clinical research on vaccines using gametocyte, or mosquito-stage
antigens (Draper et al., 2018). However, unless these have a long duration effect, a transmission-blocking vaccine would have lim-
ited value as a stand-alone intervention. Short-term transmission-blocking can already be achieved using ivermectin (which kills
mosquitoes (Chaccour and Rabinovich, 2019)), or chemotherapy (which also clears infections). Co-administration of ivermectin
with dihydroartemisinin-piperaquin e (Smit et al., 2018) thus achieves much of what a transmission blocking vaccine could do.
Monoclonal antibodies which have much longer duration of effect than drugs, may also become an alternative.
Such vaccines raise specific, but surmountable issues for regulatory agencies because they have no direct individual benefit
(Healer et al., 2017) and it is likely that they would be combined with another agent such as a sporozoite vaccine. Modelling sug-
gests that this combination will have more impact and may be more cost-effective than anti-infective vaccines alone, especially
for mass vaccination in low transmission settings (Penny et al., 2008; Tediosi et al., 2009). Both a pre-clinical and modelling stud-
ies have suggested that there are likely to be synergistic effects of this vaccine combination (Sherrard-Smith et al., 2018). An
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insensitivity, by blocking onward transmission of any parasites insensitive to anti-infective component (Smith et al., 2011;
Smith et al., 2008).
4.5. Targeting vulnerable populations and outbreaks to prevent transmission
In the longer term, for settings where burden continues to decline and elimination targets are met, anti-infective vaccines
maybe an appropriate intervention for protecting specific vulnerable groups such as pregnant women, travellers, non-immune
populations exposed to outbreak risks, or populations in conflict zones where healthcare systems and surveillance response
have broken down. Further applications may also include prevention of resurgence or prevention of reintroduction of malaria
in areas recently eliminated or close to elimination, especially if other interventions such as vector control are no longer in use.
This use-case, in particular for conflict areas or containing outbreaks, will necessarily define simple administration best with single
doses of vaccines or monoclonal antibodies.
5. Concluding remarks
In 2014, the WHO set the preferred characteristics of malaria vaccines: with an efficacy of 85% and duration of protection of a
least two years (World Health Organisation, 2015). Since this time, malaria burden, research and development of new tools and
our understanding of malaria vaccines and immune responses have significantly changed. The needs for malaria and future tools,
use-cases and key characteristics of vaccines should be revisited. The most important discussion moving forward will not neces-
sarily be to set minimum efficacy or duration targets for vaccines to reach, but rather to set the health goals malaria vaccines will
support and to define use-cases to achieve these that combine vaccines with other interventions, be they vector control, chemo-
prevention or chemotherapeutic, that support achieving our malaria health goals in different settings. Key determinants of the ef-
fectiveness and thus impact of vaccines and any new malaria tool will be the feasibility of deployment, coverage, compliance and
adherence, and should be incorporated into the use cases and product specifications. Only then should the preferred characteris-
tics of vaccines with regard to efficacy and duration of effect be considered.
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